Prolia denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prolia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Prolia Under Step Therapy

UHC's Prolia (denosumab) coverage policy typically requires that a patient try and demonstrate inadequate response to, or intolerance of, one or more oral or alternative bone-loss therapies before Prolia will be authorized. This is called a step-therapy or "fail-first" requirement. When a prescriber requests Prolia without documentation of the required prior steps — or when the documentation doesn't clearly match UHC's criteria — the claim is denied.

Step-therapy denials are highly appealable when the patient has a documented history with prior agents, or when a clinical reason exists to bypass step therapy (contraindication, intolerance, or a condition for which stepped agents are clinically inappropriate). Many states also have enacted step-therapy override laws that create an additional pathway independent of federal appeal rights.

## Your Federal Appeal Rights

Under ACA §2719 and ERISA §503:

• You may appeal on grounds that the step-therapy protocol does not apply to your specific diagnosis, or that prior steps were completed but not recognized.
• Step-therapy exception: UHC's own policies and most state laws recognize exceptions when prior agents are contraindicated, caused adverse effects, or were clinically tried and failed.
• External review is available after final internal denial; timeline is typically around four months from the final denial — confirm in your denial letter.
• Expedited review applies when standard timelines would jeopardize your health.

## The Appeal Process

1. Obtain UHC's step-therapy criteria for Prolia — specifically, the agents required and the documentation of failure or intolerance needed. 2. Compile a complete prior-treatment history: every bone-loss agent tried, the dates of use, and the documented outcome (inadequate response, adverse effect, contraindication). 3. If no prior steps were taken, ask the prescriber whether a step-therapy exception applies (intolerance risk, clinical urgency, diagnosis-specific reasons). 4. Submit the internal appeal with a structured letter from the prescriber that maps each of UHC's step requirements to specific chart entries. 5. If step therapy was completed but UHC did not recognize it, provide pharmacy records or prior EOBs as proof. 6. Check your state's step-therapy override law — your state insurance department website will have the current rule.

## Documentation to Gather

• Prior-treatment history: Medication names, start and stop dates, doses (from the prescriber's chart — you do not need to include them here), and reason for discontinuation.
• Clinical severity documentation: Current chart notes, imaging, or specialist assessments showing the clinical urgency for Prolia.
• Prescriber medical-necessity letter: Explicitly addresses each step in UHC's protocol and why the patient either completed it or qualifies for an exception.
• UHC step-therapy policy: Printed current version to confirm which agents are required.
• FDA prescribing label for Prolia: Confirms the indication and the relevant patient population.

## Criteria-Mapping Structure

List each step UHC requires in the left column. In the right column, document the corresponding chart evidence — dates of prior therapy, outcomes, and the prescriber's clinical assessment. For any step not completed, cite the exception that applies and the supporting chart evidence. This structure converts a narrative appeal into a checkable audit that reviewers can act on quickly.